Thera-SAbDab

MOSUNETUZUMAB

>   Structural Summary
TherapeuticMosunetuzumab
Target 1CD3E
Heavy Chain 1EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS
Light Chain 1DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2MS4A1
Heavy Chain 2EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
Light Chain 2DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 Structure4k7p [Fvs: YX]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Mosunetuzumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.36%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
mosunetuzumab_Fv2 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T S Y N M H W V R Q A P G K G L E W V G A I Y P G N G D T S Y N Q K F K G R F T I S V D K S K N T L Y L Q M N S L R A E D T A V Y Y C A R V V Y Y S N S Y W Y F D V W G Q G T L V T V S S
4k7p E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T S Y N M H W V R Q A P G K G L E W V G A I Y P G N G A T S Y N Q K F K G R F T I S V D K S K N T L Y L Q M N S L R A E D T A V Y Y C A R V V Y Y S A S Y W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
mosunetuzumab_Fv2 D I Q M T Q S P S S L S A S V G D R V T I T C R A S S S V S - Y M H W Y Q Q K P G K A P K P L I Y A P S N L A S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q W S F N P P T F G Q G T K V E I K
4k7p D I Q M T Q S P S S L S A S V G D R V T I T C R A S S S V - S Y L H W Y Q Q K P G K A P K P L I Y A P S N L A S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q W A F N P P T F G Q G T K V E I K
>   Metadata
FormatBispecific mAb
IsotypeG1
Highest Clinical Trial (Jan '20)Phase-I/II
Estimated Status (Jan '20)Active
Recorded Developmental Technologyna
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedGenentech
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma, Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]